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OBJECTIVE — To characterize the amount of nocturnal hypoglycemia and evaluate factors
associatedwithnocturnalhypoglycemiaassessedwithcontinuousglucosemonitoring(CGM)in
adults and children with type 1 diabetes who participated in the Juvenile Diabetes Research
Foundation CGM randomized clinical trial.
RESEARCH DESIGN AND METHODS — The analysis included 36,467 nights with
4 h of CGM glucose readings between 12 midnight and 6:00 A.M. from 176 subjects assigned
to the CGM group of the trial. The percentage of nights in which hypoglycemia occurred (two
consecutive CGM readings 60 mg/dl in 20 min) was computed for each subject. Associations
with baseline characteristics and clinical factors were evaluated using a multivariate regression
model.
RESULTS — Hypoglycemiceventsoccurredduring8.5%ofnights,withthemedianpercent-
age of nights with hypoglycemia per subject being 7.4% (interquartile range 3.7–12.1%). The
duration of hypoglycemia was 2 h on 23% of nights with hypoglycemia. In a multivariate
model,ahigherincidenceofnocturnalhypoglycemiawasassociatedwith1)lowerbaselineA1C
levels(P0.001)and2)theoccurrenceofhypoglycemiaononeormorenightsduringbaseline
blinded CGM (P  0.001). The hypoglycemia frequency was not associated with age or with
insulin modality (pump versus multiple daily injections).
CONCLUSIONS — Nocturnal hypoglycemia is frequent and often prolonged in adults and
children with type 1 diabetes. Patients with low A1C levels are at an increased risk for its
occurrence.OneweekofblindedCGMcanidentifypatientswhoareatgreaterriskfornocturnal
hypoglycemia.
Diabetes Care 33:1004–1008, 2010
E
ven with the use of insulin pumps
and long-acting insulin analogs, se-
verehypoglycemiaiscommoninpa-
tients with type 1 diabetes, especially
during sleep at night. In the Diabetes
Control and Complications Trial, more
than half of severe hypoglycemic events
occurredduringsleep(1),andotherstud-
ies have shown an even greater incidence
of severe nocturnal hypoglycemic events
in type 1 diabetes (2). Moreover, Sovik
and Thordarson (3) reported that among
patients aged 40 years who died over a
10-yearperiod,6%ofthedeathsweredue
to “dead-in-bed” syndrome, which in
manyinstancesprobablywastheresultof
severe nocturnal hypoglycemia. Delayed
glucose-lowering effects of afternoon ex-
ercise (4), sleep-induced defects in coun-
terregulatory hormone responses to
hypoglycemia (5–7), and missed bedtime
snacks (8) are among the contributing
causes of severe nocturnal hypoglycemic
events.
Studies that used retrospective and
real-time continuous glucose monitoring
(CGM)systemstoassessglycemiccontrol
of type 1 diabetes indicate that severe hy-
poglycemic events are only the tip of the
icebergregardingtheriskofnocturnalhy-
poglycemia, because many more events
are unrecognized and asymptomatic (8–
14). Detection of such events is impor-
tant,however,becauserecurrentepisodes
ofmildhypoglycemiahavebeenshownto
contribute to the development of defec-
tive counterregulatory hormone re-
sponses to subsequent reductions in
blood glucose, thus setting the stage for
clinicallyimportanthypoglycemicevents.
Buckingham et al. (15) documented four
episodes of seizures occurring during the
night in patients wearing CGM devices,
which demonstrated that there were
21⁄4–4 h of low sensor glucose values pre-
ceding each seizure.
Our Juvenile Diabetes Research
Foundation (JDRF) CGM Study Group
recently reported the results of a 6-month
randomizedclinicaltrialand6-monthex-
tension study that evaluated the effective-
ness of real-time CGM in intensively
treatedtype1diabeticsubjectswithbase-
line A1C levels 7.0% (n  322) and
7.0%(n129)(16–18).Thesestudies
have provided a very large dataset of
nighttime CGM proﬁles to evaluate the
frequency of nocturnal hypoglycemia
during 12 months of CGM use in the
home environment and factors associated
with greater risk.
RESEARCH DESIGN AND
METHODS— Thestudyprotocoland
clinical characteristics of enrolled sub-
jects have been described in detail else-
where (16,17,19). Major eligibility
criteria included age 8 years, type 1 di-
abetes for at least 1 year, use of either an
insulin pump or multiple (at least three)
daily insulin injections, and A1C level
10.0%. The dataset used for the current
analyses included 180 subjects assigned
to the CGM group who used either the
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Care, Alameda, CA) or the MiniMed Par-
adigm REAL-Time Insulin Pump and
Continuous Glucose Monitoring System
(Medtronic MiniMed, Northridge, CA).
At baseline, a blinded CGM device was
used for 1 week. Thereafter, the goal was
to use the unblinded CGM device on a
daily basis if possible. CGM glucose data
were downloaded at each visit over 12
months of follow-up. Subjects and par-
ents of minor subjects completed the Hy-
poglycemia Fear Survey (20) at baseline,
6 months, and 12 months.
The CGM data were evaluated from
midnight to 6:00 A.M. Only nights having
at least4ho fglucose data were included
in the analysis. Subjects needed to have at
least 42 such nights to be included in the
analysis (this restriction was placed be-
cause hypoglycemia rates were calculated
per subject). Four subjects did not meet
thiscriterionandwerenotincludedinthe
analysis. The dataset included 36,467
nights from 176 subjects with a median
value of 217 nights per subject. Of the
nights, 86% had the full6ho fdata with-
out any skips from midnight to 6:00 A.M.
A hypoglycemia event was deﬁned as the
occurrence of at least two CGM glucose
values 60 mg/dl within a 20-min pe-
riod. The percentage of nights with at
least one hypoglycemia event was com-
puted for each subject.
The associations between nocturnal
hypoglycemia rate, deﬁned as the per-
centage of nights with hypoglycemia per
subject, and baseline demographic and
clinical factors (listed in Table 1) were
evaluated using regression models. Be-
cause of the skewed distribution of the
hypoglycemia rate, a rank transformation
(van der Waerden scores) was used in the
models. Baseline demographic and clini-
cal factors with P  0.20 in the univariate
model were included in an initial multi-
variate model and then a backward elim-
ination procedure was used to remove
variables with P  0.05. A forward selec-
tion process resulted in a similar model.
Age was evaluated as a discrete factor in
three prespeciﬁed levels (8–14, 15–24,
and 25 years). To avoid collinearity in
the model building, the highly correlated
baseline hypoglycemic measures (per-
centage of daytime, nighttime, or 24 h
with hypoglycemia and number of nights
with hypoglycemia) and other baseline
glycemic measures (the percentage of
blinded CGM values between 71 and 180
mg/dl, the percentage of values 250
mg/dl, and A1C) were included in the
model one at a time. Subjects with miss-
Table 1—Baseline characteristics
Overall
Age-group
8–14 years 15–24 years 25 years
n 176 64 42 70
Age (years) 25.6  15.6 11.6  2.0 19.6  3.2 42.1  11.4
Diabetes duration (years) 14.7  12.5 6.1  3.1 10.2  5.1 25.4  13.2
Sex
Female 94 (53) 34 (53) 21 (50) 39 (56)
Male 82 (47) 30 (47) 21 (50) 31 (44)
Severe hypoglycemia events in 6 months before study
(self-reported)
0 164 (93) 61 (95) 39 (93) 64 (91)
1 12 (7) 3 (5) 3 (7) 6 (9)
Nights with hypoglycemia during blinded use at
baseline*
0 102 (60) 42 (67) 21 (51) 39 (59)
1 68 (40) 21 (33) 20 (49) 27 (41)
Home blood glucose meter measurements per day
(self-reported at baseline)†
6.8  2.3 6.8  2.0 6.0  2.1 7.1  2.5
5 43 (29) 12 (23) 16 (52) 15 (23)
6–8 78 (53) 31 (60) 12 (39) 35 (55)
8 26 (18) 9 (17) 3 (10) 14 (22)
Insulin delivery
Pump 163 (93) 57 (89) 38 (90) 68 (97)
Multiple daily injections 13 (7) 7 (11) 4 (10) 2 (3)
A1C 7.4  0.9 7.6  1.0 7.6  0.8 7.1  0.8
7.0% 57 (32) 17 (27) 11 (26) 29 (41)
7.0–8.0% 72 (41) 22 (34) 16 (38) 34 (49)
8.0% 47 (27) 25 (39) 15 (36) 7 (10)
Hypoglycemia Fear Scale score‡ 28  18 25  17 29  18 31  18
20 65 (37) 27 (42) 15 (36) 23 (33)
20–30 32 (18) 14 (22) 8 (19) 10 (14)
30 78 (45) 22 (35) 19 (45) 37 (53)
Data are means  SD or n (%). *From use of a blinded CGM device for 1 week at baseline, missing for 6 subjects. †Collected on randomization form, as assessed
by clinic personnel over the last 7 days. A question was added to Case Report Form after study initialization, and data were missing for 29 subjects. ‡The
Hypoglycemia Fear Scale consists of 15 5-point Likert scale items, with scores scaled to a 0–100 range with higher scores indicating more fear of hypoglycemia;
missing for 1 subject.
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from the corresponding univariate mod-
els. For the multivariate models, missing
was treated as a separate category for
discrete covariates and an indicator for
missing was added to the model for con-
tinuous covariates. The association of age
andhypoglycemiadurationduringnights
with a hypoglycemic event was evaluated
using repeated-measures regression with
rank scores. The comparison of the hypo-
glycemia rate in the ﬁrst 6 months and in
the second 6 months was based on rank
scores.
Analyses were conducted using SAS
(version 9.1, SAS Institute, Cary, NC). All
P values are two-sided. Because of the ex-
ploratory nature of these analyses and the
multiple statistical tests, the threshold for
statisticalsigniﬁcancewasadjustedtoP
0.01.
RESULTS— The clinical characteris-
tics of the 176 subjects who met the cri-
teria for inclusion in these analyses are
shown in Table 1. Hypoglycemic events
occurredbetweenmidnightand6:00 A.M.
during3,083(8.5%)ofthe36,467nights,
withthemedianpercentageofnightswith
hypoglycemiapersubjectbeing7.4%(in-
terquartile range 3.7–12.1%), which is
approximately twice per month. The
maximum percentage of hypoglycemic
nights per subject was 27.8%; six (3%) of
subjects had no hypoglycemic nights
(number of nights for these subjects
rangedfrom55to235,theirbaselineA1C
rangedfrom7.7to8.9%)(supplementary
Table 1, available in an online appendix
at http://care.diabetesjournals. org/cgi/
content/full/dc09-2081/DC1).
Onthe3,083nightsduringwhichhy-
poglycemia occurred, the median dura-
tionofhypoglycemia(60mg/dl)was53
min (interquartile range 29–110 min)
andthemeanwas8175min,with47%
of nights having at least1ho fhypoglyce-
mia,23%atleast2h,and11%atleast3h.
An exploratory plot of the duration of
hypoglycemia versus age suggested a
shorter mean duration of the events in
subjects aged 25 years old than in
those aged 25 years old (Fig. 1). In a
statistical comparison of these two age-
groups,meandurationofhypoglycemia
during the nights on which hypoglyce-
mia occurred was 73 min in subjects
aged 25 years and 88 min in subjects
aged 25 years (median 50 vs. 58 min,
P  0.007).
As shown in Table 2, a higher inci-
denceofnocturnalhypoglycemiaoverthe
12 months of follow up was associated
with 1) lower baseline A1C levels (P 
0.001) and 2) the occurrence of hypogly-
cemia on one or more nights during base-
line blinded CGM use (P  0.001) in a
multivariate model. Similar results were
obtainedwhenthepercentageofdaytime,
nighttime, or 24 h with hypoglycemia
duringthebaselineblindedCGMusewas
includedinthemodelinsteadofthenum-
ber of nights with hypoglycemia and
whenthepercentageofblindedCGMval-
uesbetween71and180mg/dlortheper-
centage of values 250 mg/dl was
included in the model instead of A1C
(supplementary Table 2).
There was a suggestion of an upside
down U-shaped association between age
and hypoglycemia rate. The median hypo-
glycemia rate was 6.3% in the 8- to 14-year
age-group, 8.8% in the 15- to 24-year age-
group, and 7.4% in the 25-year age-
group (univariate P  0.05, multivariate
P  0.12). The frequency of nocturnal hy-
poglycemia was not statistically different
between pump and multiple daily injection
users (P0.63). Scores on the Hypoglyce-
mia Fear Survey completed at baseline also
werenotpredictiveofthefrequencyofnoc-
turnalhypoglycemia.Thefactorsassociated
with hypoglycemia appeared to be similar
inthethreeage-groups(supplementaryTa-
ble 2). The median hypoglycemia rate was
6.6% (25th and 75th interquartile range
3.5, 12.6%) in the ﬁrst 6 months and 7.7%
(3.7, 13.6%) in the second 6 months (P 
0.45).
CONCLUSIONS — The 36,000
nights with 4 h of sensor glucose read-
ings,totaling2.4millionindividualglu-
cose values in 176 patients with type 1
diabetes, aged 8–72 years, provided us
with a unique opportunity to determine
thefrequencyofnocturnalhypoglycemia.
DuringtreatmentaimedtolowerA1Clev-
els to 7.0%, as has been suggested in
other smaller studies, the occurrence of
nocturnal hypoglycemia in our inten-
sively treated subjects was both frequent,
occurringon8.5%ofnightsduringthe12
months of CGM use, and prolonged. On
23% of hypoglycemic nights, sensor glu-
cose levels 60 mg/dl were present for
almost 2 h and the duration of hypogly-
cemia was longer in those aged 25
years. It seems unlikely that the observed
incidence of nocturnal hypoglycemia is
an overestimate because prior outpatient
studies using CGM have reported even
higher rates (8,9,11–13), as have inpa-
tient studies using blood glucose mea-
surements (10,14). Although sensor
inaccuracy could produce misclassiﬁca-
tion of some nights as to whether hypo-
glycemia occurred, an inpatient accuracy
study conducted by the Diabetes Re-
search in Children Network using the
FreeStyleNavigatorshowedthatthefalse-
positive and false-negative rates for noc-
turnal hypoglycemia were approximately
the same (21). Thus, the point estimate of
nocturnal hypoglycemia from the current
study is unlikely to be appreciably af-
fected by sensor inaccuracy.
Figure 1—Duration of hypoglycemia (60 mg/dl) vs. age. For presentation purposes, the hypo-
glycemic nights ordered by age were divided into 20 groups with an approximately equal number
ofnightspergroup.Theaveragedurationwasthenplottedagainsttheaverageageforeachgroup.
The regression line, however, is based on all the data points, not the 20 groups.
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ratherthan70mg/dlwasusedtodeﬁne
hypoglycemia because there is consider-
ably greater concern for serious sequelae
for glucose levels 60 mg/dl than for lev-
els between 61 and 70 mg/dl. Moreover,
in our study of sensor glucose levels in 8-
to 65-year-old, healthy, nonobese sub-
jectswithnormalfastingglucoseandnor-
mal glucose tolerance, nighttime sensor
glucosevalues60mg/dlweremuchless
common than values between 61 and 70
mg/dl (median frequency 0.0 vs. 1.0%,
respectively, P  0.001) (22).
Not surprisingly, the frequency of
nighttime hypoglycemia was greater in
subjects with lower A1C values and in
those who had the occurrence of noctur-
nal hypoglycemia during a week of
blindedCGMuseatbaseline.Themethod
of insulin administration was not a signif-
icant predictor, but the number of pa-
tients using multiple daily injections was
small, limiting the interpretation of this
ﬁnding. It also is important to note that
nocturnal hypoglycemia was frequent
and prolonged in our subjects even
though nighttime CGM proﬁles were
being used to adjust overnight basal
rates, and long-acting insulin analog
doses and sensor alarms were used to
limitthedurationofnocturnalhypogly-
cemic events.
These results support the contention
that overnight insulin replacement may
never be optimal in patients with type 1
diabetes until closed-loop systems that
provide minute-to-minute feedback con-
trol of insulin delivery based on real-time
sensor glucose sensor data are developed
for home use.
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Table 2—Association of baseline factors and nocturnal hypoglycemia
n
% Nights with
hypoglycemia per subject
Unadjusted
P value Model 1* Model 2†
Total 176 7.4 (3.7, 12.1)
Age 0.05 0.12
8–14 years 64 6.3 (2.0, 11.4)
15–24 years 42 8.8 (3.9, 16.1)
25 years 70 7.4 (4.6, 10.8)
Sex 94 7.2 (3.7, 10.8)
Female 0.36
Male 82 7.8 (3.7, 14.2)
Severe hypoglycemia events in 6 months before
to study (self-reported)
0.87
0 164 7.2 (3.7, 12.2)
1 12 8.3 (4.3, 10.5)
Nights with hypoglycemia during blinded use
at baseline‡
0.001 0.001 0.001
0 102 6.0 (2.8, 10.5)
1 68 9.4 (5.1, 15.9)
Home blood glucose meter measurements per
day (self-reported at baseline)§
0.28
5 43 8.1 (4.1, 13.7)
6–8 78 8.8 (3.7, 12.2)
8 26 5.4 (3.2, 12.4)
Insulin delivery
Pump 163 7.4 (3.9, 12.0) 0.63
Multiple daily injections 13 5.1 (1.8, 12.6)
A1C§ 0.001 0.001 0.001
7.0% 57 9.0 (5.3, 14.7)
7.0–8.0% 72 8.2 (4.5, 12.0)
8.0% 47 3.9 (1.6, 8.7)
Hypoglycemia Fear Scale score§¶ 0.11 0.22
20 65 7.5 (3.3, 10.3)
20–30 32 7.7 (4.6, 11.0)
30 78 7.0 (3.7, 13.5)
Data are median (25th, 75th percentile). *The multivariate regression model included all variables with P  0.20. †Multivariate regression model using backward
selection keeping those variables with P  0.05. ‡From use of a blinded CGM device for 1 week at baseline, missing for 6 subjects. §P value obtained by treating as
continuous variable. Collected on a randomization form, as assessed by clinic personnel over the last 7 days. A question was added to Case Report Form after study
initialization, and data were missing for 29 subjects. ¶The Hypoglycemia Fear Scale consists of 15 5-point Likert scale items, with scores scaled to a 0 to 100 range
with higher scores indicating more fear of hypoglycemia; missing for 1 subject.
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